External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Immunology Respiratory Disorder

Respiratory Disorder

What's new

Sign up or login to unlock the full suite of MEDICALLY features
Nov 9 / Roche and Genentech
Impact of Baseline Characteristics on Long-term Response Following Omalizumab▼ Treatment in Patients with Allergic Asthma
This poster examined the impact of baseline patient characteristics on long-term response to omalizumab▼ in patients with allergic asthma.
Immunology Respiratory Disorder ACAAI-2023

Sign up or login to unlock the full suite of MEDICALLY features
Nov 9 / Roche and Genentech
Impact of Baseline Characteristics on Long-term Response Following Omalizumab Treatment in Patients with Allergic Asthma
This poster examined the impact of baseline patient characteristics on long-term response to omalizumab in patients with allergic asthma.
Immunology Respiratory Disorder ACAAI-2023
Upcoming congresses
Access to Roche and Genentech’s latest medical information
View related congresses

Ask a question or share feedback

Get in touch

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.